These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
542 related articles for article (PubMed ID: 26681753)
1. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties. Nguyen SD; Maaninka K; Lappalainen J; Nurmi K; Metso J; Öörni K; Navab M; Fogelman AM; Jauhiainen M; Lee-Rueckert M; Kovanen PT Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):274-84. PubMed ID: 26681753 [TBL] [Abstract][Full Text] [Related]
2. Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr Kareinen I; Baumann M; Nguyen SD; Maaninka K; Anisimov A; Tozuka M; Jauhiainen M; Lee-Rueckert M; Kovanen PT J Lipid Res; 2018 Jun; 59(6):945-957. PubMed ID: 29581158 [TBL] [Abstract][Full Text] [Related]
3. Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase. Implications for HDL function. Lee M; Uboldi P; Giudice D; Catapano AL; Kovanen PT J Lipid Res; 2000 Jun; 41(6):975-84. PubMed ID: 10828090 [TBL] [Abstract][Full Text] [Related]
4. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Lee M; Calabresi L; Chiesa G; Franceschini G; Kovanen PT Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1475-81. PubMed ID: 12231569 [TBL] [Abstract][Full Text] [Related]
5. Detection of chymase-digested C-terminally truncated apolipoprotein A-I in normal human serum. Usami Y; Matsuda K; Sugano M; Ishimine N; Kurihara Y; Sumida T; Yamauchi K; Tozuka M J Immunol Methods; 2011 Jun; 369(1-2):51-8. PubMed ID: 21497162 [TBL] [Abstract][Full Text] [Related]
6. Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model. Li J; Wang W; Han L; Feng M; Lu H; Yang L; Hu X; Shi S; Jiang S; Wang Q; Ye L Acta Biochim Biophys Sin (Shanghai); 2017 Feb; 49(2):149-158. PubMed ID: 28069582 [TBL] [Abstract][Full Text] [Related]
7. Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity. Dinnes DL; White MY; Kockx M; Traini M; Hsieh V; Kim MJ; Hou L; Jessup W; Rye KA; Thaysen-Andersen M; Cordwell SJ; Kritharides L FASEB J; 2016 Dec; 30(12):4239-4255. PubMed ID: 27630170 [TBL] [Abstract][Full Text] [Related]
8. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Di Bartolo BA; Nicholls SJ; Bao S; Rye KA; Heather AK; Barter PJ; Bursill C Atherosclerosis; 2011 Aug; 217(2):395-400. PubMed ID: 21571275 [TBL] [Abstract][Full Text] [Related]
9. Recombinant lectin-like domain of thrombomodulin suppresses vascular inflammation by reducing leukocyte recruitment via interacting with Lewis Y on endothelial cells. Lin WL; Chang CF; Shi CS; Shi GY; Wu HL Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2366-73. PubMed ID: 23950139 [TBL] [Abstract][Full Text] [Related]
10. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Lee M; von Eckardstein A; Lindstedt L; Assmann G; Kovanen PT Arterioscler Thromb Vasc Biol; 1999 Apr; 19(4):1066-74. PubMed ID: 10195937 [TBL] [Abstract][Full Text] [Related]